Novel Drug Candidates for Obstetric and Gynecological Diseases

Request Number REQ4349252
Due Date September 21, 2017
Request for Proposal Details
RFP Title
Novel Drug Candidates for Obstetric and Gynecological Diseases
RFP Description

NineSigma, representing a pharmaceutical company with special focus on obstetric and gynecological area, seeks novel drug candidates for the treatment of obstetric and gynecological diseases.


The client, with high level of expertise in drug discovery research and clinical development in this area, has been aiming at expanding their product portfolio and pipeline.


The obstetric and gynecological diseases are medical conditions with high unmet medical needs, therefore, development of novel drugs are highly anticipated. The client strives for early launch of a new drug in order to provide new treatment options to patients.


The client has thus issued this open request in order to collaborate with external organizations that possesses promising drug candidate.


Respondents should submit proposals using the attached Response Template.


The client will review submitted proposals and possibly ask clarifying questions before selecting the most suitable candidates for collaboration. The client will select the best candidate(s) through evaluations. During the selection process, the client may execute non-disclosure agreements (NDA) with selected respondent(s), seek further information disclosure, and discuss specific development targets or potential opportunities. The client will execute necessary agreement(s) with the selected respondent(s) and move to the advanced development phase. Specifics of any collaboration will be determined through consultation with the concerned parties.


Key Success Criteria

Target diseases
This open request targets obstetric and gynecological diseases except for cancer. Target diseases include, but are not limited to, the following, but other drugs for the treatment of obstetric and gynecological disease are also anticipated:
  • Endometriosis
  • Adenomyosis uteri
  • Uterine myoma
  • Polycystic ovarian syndrome
Requirements for drug candidates
The client seeks drug candidates that meet the following requirements:
  • Modality:
    • Low molecular weight compounds, antibodies, peptides, proteins, and diagnostic biomarkers
  • The mechanism of action should be different from existing drugs 
    • However, candidates with a known mechanism that can be clearly differentiated from existing drugs are acceptable.
  • High efficacy and safety can be expected
    • For safety, it is required that data has been obtained from a non-clinical study or adverse events are considered very unlikely to occur from the point of mechanism.
  • Development level:
    • The  stage should be from pre-clinical study to Phase I trial
    • Optimization of the compound has been completed and the candidate can be presented
  • A GLP-Tox study need not necessarily have been conducted.


Approaches not of interest

The following drug candidates are out of the scope:
  • Candidates for cancer drugs
  • The drug candidates in the phase II trial


Preferred Collaboration types
  • Joint Development
  • Technology Licensing
Items to be submitted

Responses will use the Proposal Template which is linked to the “attachments“ shown at the bottom of the link <REQ4349252> and include the following items:
  • Target diseases
  • Overview of the proposed candidate (modality, route of administration, mechanism of action, etc.)
  • Examples (pharmacology, safety, toxicity, pharmacokinetics, etc.)
  • Current research and development stage
  • Future research plans
  • Any requests concerning the collaboration
  • Status of intellectual property related to the  proposed technology
  • Research achievements

Area of Interest
Request Priority